ArticleAmerican journal of preventive cardiology2024
Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a).
Article in American journal of preventive cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of Aspirin on Primary Prevention of Cardiovascular Events in Patients with Elevated Lipoprotein(a): A Systematic Review and Meta-analysis.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Pooled it
- The Roles of Lipoprotein(a) in Atherosclerosis - Minding the Knowledge Gaps.Current atherosclerosis reports · 2026Review
- Lipoprotein(a) as a Cardiovascular Risk Factor: Clinical Significance and Therapeutic Perspectives.Biomedicines · 2026Review
- Inherited risk of coronary artery disease: redefining care with imaging and genetics.Nature reviews. Cardiology · 2026Review
- Aspirin in Primary Prevention of CVD: A Pragmatic Outline and Advice for Treatment Personalization.Journal of clinical medicine · 2026Review
- Modeling Benefit of Aspirin According to Lp(a) and Coronary Artery Calcium: MESA.JACC. Cardiovascular imaging · 2026Article
- The role of Lipoprotein(a) and oxidized phospholipids in modifying the effects of aspirin on major cardiovascular events and bleeding in the ASPirin in Reducing Events in the Elderly (ASPREE) randomized clinical trial: Statistical analysis plan.medRxiv : the preprint server for health sciences · 2026Article
- Progress in risk assessment and management: Forecasting updates across international cholesterol guidelines.American journal of preventive cardiology · 2026Review
- Trends in lipoprotein(a) testing and impact on clinical care: A contemporary systemwide analysis.American journal of preventive cardiology · 2026Article
- Bundled measurement of LDL-cholesterol, lipoprotein(a), and high sensitivity C-reactive protein across the spectrum of cardiovascular risk.American journal of preventive cardiology · 2026Article
- Genetic Evidence Linking Lipoprotein(a) to Cardiovascular Disease and the Potential Role of Aspirin: A Mendelian Randomization Study.Reviews in cardiovascular medicine · 2025Article
- Lipoprotein(a) at a "Tipping Point": case to move to universal screening.American journal of preventive cardiology · 2025Review
- Lipoprotein (a) in primary cardiovascular disease prevention is actionable today.American heart journal plus : cardiology research and practice · 2025Review
- Identification and management of patients at high-risk for cardiovascular disease in primary prevention.American journal of preventive cardiology · 2025Review
- Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications.Diabetes, obesity & metabolism · 2025Review
- Traditional risk factors, optimal cardiovascular health, and elevated lipoprotein(a).European journal of preventive cardiology · 2025Article
- Future of Stroke Prevention: 7 Updates in the 2024 AHA/ASA Primary Prevention of Stroke Guideline.JACC. Advances · 2025Article
- Role of Aspirin in Reducing Risk for Atherosclerotic Cardiovascular Disease in Individuals with Elevated Lipoprotein(a).Current atherosclerosis reports · 2025Review
- Rosuvastatin-based combination treatment with acetylsalicylic acid or ezetimibe in the management of patients at high and very high cardiovascular risk. Expert opinion paper of the Polish Lipid Association 2025.Archives of medical science : AMS · 2025Article
- 2024: The year in cardiovascular disease - the year of lipoprotein(a). Research advances and new findings.Archives of medical science : AMS · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Objective: Lipoprotein(a) [Lp(a)] is an atherogenic and prothrombotic lipoprotein associated with atherosclerotic cardiovascular disease (ASCVD). We assessed the association between regular aspirin use and ASCVD mortality among individuals Methods: Eligible participants were aged 40-70 years without clinical ASCVD, reported on aspirin use, and had Lp(a) measurements from the Third National Health and Nutrition Examination Survey (NHANES III, 1988-1994), the only cycle of this nationally representative US cohort to measure Lp(a). Regular aspirin use was defined as taking aspirin ≥30 times in the previous month. Using NHANES III linked mortality records and weighted Cox proportional hazards regression, the association between regular aspirin use and ASCVD mortality was observed in those Results: Among 2,990 persons meeting inclusion criteria (∼73 million US adults), the mean age was 50 years, 86% were non-Hispanic White, 9% were non-Hispanic Black, 53% were female, and 7% reported regular aspirin use. The median Lp(a) was 14 mg/dL and the proportion with elevated Lp(a) was similar among those Conclusion: Regular aspirin use was associated with significantly lower ASCVD mortality in adults without clinical ASCVD who had elevated Lp(a). These findings may have clinical and public health implications for aspirin utilization in primary prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.